

	Type	L #	Hits	Search Text	DBs	Time Stamp	Co mm en ts	Err or Def ini tio n	Er ro rs
1	BRS	L1	49064	retinoid or choleciferol or (vitamin adj K) or tocopherol or (ascorbic adj acid)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:20			0
2	BRS	L2	1010	n-acetylcysteine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 17:14			0
3	BRS	L3	1505	acetylcysteine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 17:14			0
4	BRS	L4	213	1 same (2 or 3)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:20			0
5	BRS	L6	39	oxygen adj labile	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 17:16			0
6	BRS	L7	0	5 same 6	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 17:16			0
7	BRS	L5	74	composition same 4	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 17:16			0
8	BRS	L8	101	retinoid same tocopherol same (ascorbic adj acid)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:32			0
9	BRS	L9	0	8 same (2 or 3)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:32			0
10	BRS	L10	46197	choleciferol or (vitamin adj K) or tocopherol or (ascorbic adj acid)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:21			0
11	BRS	L11	3	retinoid same 10 same (2 or 3)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:23			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Co mm en ts	Err or Def ini tio n	Er ro rs
12	BRS	L12	171926	niacin or thiamine or riboflavin or (folic adj acid) or pyrodoxine or (pantothenic adj acid) or niacinamide or (lipoic adj acid) or (dihydrolipoic adj acid) or (amino adj acid)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:27			0
13	BRS	L13	4	5 same 12	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:27			0
14	BRS	L14	191	retinoid same (ascorbic adj acid)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:32			0
15	BRS	L15	0	14 same (2 or 3)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:32			0
16	BRS	L16	562480	humectant or antioxidant or preservative or fragrance or (surface adj active adj agent) or binder or (skin adj protectant adj agent)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:35			0
17	BRS	L17	27	5 same 16	USPAT; US-PGPUB; EPO; JPO; DERWENT	2002/04/2 4 18:36			0

> d his

(FILE 'HOME' ENTERED AT 19:13:14 ON 24 APR 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'
ENTERED AT

19:13:53 ON 24 APR 2002

L1 311380 S RETINOID OR CHOLECIFEROL OR (VITAMIN K) OR
TOCOPHEROL OR (ASC

L2 24378 S N-ACETYLCYSTEINE OR ACETYLCYSTEINE

L3 767 S L1 (P) L2

L4 12 S L3 (P) COMPOSITION

L5 12 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)

L6 67 S RETINOID (P) TOCOPHEROL (P) (ASCORBIC ACID)

L7 5 S L6 (P) L2

L8 1 DUPLICATE REMOVE L7 (4 DUPLICATES REMOVED)

L9 1 S L8 NOT L5

L10 177 S RETINOID (P) (ASCORBIC ACID)

L11 5 S L10 (P) L2

L12 1 DUPLICATE REMOVE L11 (4 DUPLICATES REMOVED)

L13 0 S L12 NOT (L9 OR L4)

=> log y

FILE 'HOME' ENTERED AT 19:13:14 ON 24 APR 2002

=> file medline caplus biosis embase scisearch agricola		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 19:13:53 ON 24 APR 2002

FILE 'CAPLUS' ENTERED AT 19:13:53 ON 24 APR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 19:13:53 ON 24 APR 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 19:13:53 ON 24 APR 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 19:13:53 ON 24 APR 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 19:13:53 ON 24 APR 2002

=> s retinoid or choleciferol or (vitamin K) or tocopherol or (ascorbic acid)
L1 311380 RETINOID OR CHOLECIFEROL OR (VITAMIN K) OR TOCOPHEROL OR (ASCORB
IC ACID)

=> s n-acetylcysteine or acetylcysteine
L2 24378 N-ACETYLCYSTEINE OR ACETYLCYSTEINE

=> s l1 (p) l2
L3 767 L1 (P) L2

=> s l3 (p) composition
L4 12 L3 (P) COMPOSITION

=> duplicate remove l4
DUPLICATE PREFERENCE IS 'CAPLUS, BIOSIS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L4
L5 12 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)

=> d 15 1-12 ibib abs

L5 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:688083 CAPLUS
DOCUMENT NUMBER: 133:271679
TITLE: Ascorbic acid composition and method for treatment of
aging or damaged skin
INVENTOR(S): Meisner, Lorraine F.
PATENT ASSIGNEE(S): Bioderm, Inc., USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056327	A1	20000928	WO 2000-US6886	20000316
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, IE, IT, LU, MC, NL, PT, SE, B, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6217914 B1 20010417 US 1999-356142 19990719
BR 2000009158 A 20011226 BR 2000-9158 20000316
EP 1185260 A1 20020313 EP 2000-919421 20000316

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:

US 1999-125356P P 19990319
US 1999-356142 A 19990719
WO 2000-US6886 W 20000316

AB An ascorbic acid-based compn. and related method for the treatment of aging or photo-damaged skin is disclosed. The compn. includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temp. and concn. conditions. The compn. typically includes at least about 5.0 % (wt./vol.) ascorbic acid and may advantageously be formulated to have a pH above 3.5. Generally, the compn. also includes non-toxic zinc salt, tyrosine compd., and/or cosmetically acceptable carrier. In addn., the compn. may include an anti-inflammatory compd., such as aminosugar and/or sulfur-contg. anti-inflammatory compd. The topical compn. may be in the form of a serum, a hydrophilic lotion, an ointment, a cream, or a gel.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:688043 CAPLUS

DOCUMENT NUMBER: 133:256834

TITLE: Composition for medicated chewing gums, process for manufacturing the same, and tablets so obtained

INVENTOR(S): Badetti, Rolando

PATENT ASSIGNEE(S): ATP Avant-Garde Technologies and Product Marketing and Licensing S.A., Switz.

SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056281	A1	20000928	WO 1999-EP7917	19991018
W:				
AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9962037	A1	20001009	AU 1999-62037	19991018
EP 1162946	A1	20011219	EP 1999-949008	19991018
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9917220	A	20011226	BR 1999-17220	19991018

PRIORITY APPLN. INFO.:

IT 1999-MI571 A 19990322
US 1999-387538 A 19990831
WO 1999-EP7917 W 19991018

AB Disclosed is a ***compn*** for medicated chewing gums having the active principle dispersed in the gum and coated by a mixt. consisting of a water-sol. element and a water-insol. one. The principle can be one or more from the group consisting of nicotine, ibuprofen, paracetamol, dextromethorphan, dimenhydrinate, ginger, L- ***ascorbic***, ***acid*** (vitamin C), ***acetylcysteine***, ephedrine, d-pseudoephedrine, valerian, ranitidine, chlorhexidine, tibenzonium iodide, preferably nicotine while the sol. element is a carbohydrate, preferably sorbitol and the water-insol. element is an oil, preferably hydrogenated castor oil. A process for manufg. a tablet of medicated chewing gum having the ***compn*** according to the invention is also described. The tablet according to the invention has highly stable organoleptic properties and gradual and controlled release properties.

L5 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:839120 CAPLUS
DOCUMENT NUMBER: 134:21446
TITLE: Compositions for stabilizing oxygen-labile
pharmaceuticals
INVENTOR(S): Kung, John; Liu, Jue-chen
PATENT ASSIGNEE(S): Johnson & Johnson Consumer Companies, Inc., USA
SOURCE: Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1055720	A2	20001129	EP 2000-304519	20000526
EP 1055720	A3	20010307		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2309520	AA	20001128	CA 2000-2309520	20000525
JP 2001011441	A2	20010116	JP 2000-158635	20000529
CN 1284327	A	20010221	CN 2000-118833	20000529
BR 2000003780	A	20010403	BR 2000-3780	20000616
PRIORITY APPLN. INFO.:		US 1999-136442P	P	19990528
		US 1999-361425	A	19990727

AB This invention relates to ***compsns*** and methods for stabilizing oxygen-labile species. More particularly, it relates to ***compsns*** contg. 1 or more oil- and/or water-sol. oxygen-labile species and one or more stabilizing elements. It also relates to methods of making such ***compsns*** and methods of using such ***compsns***. Thus, a formulation contained water 73.96, disodium EDTA 0.20, phenoxyethanol 0.73, methylparaben 0.20, propylparaben 0.07 and hydroxyethyl cellulose 1.00% for the water phase; BHT 0.10, GMS 2.00 cetearyl glucoside 3.000, C12-15 alkyl benzoate 2.00, avobenzone 2.00, octyl methoxycinnamate 4.00, and ascorbyl palmitate 0.50% for the oil phase; ***ascorbic*** ***acid*** 5.00, ***tocopherol*** 0.05, retinol 0.25, lactoferrin and thioxanthine and uric acid 1.00, ***N*** - ***acetylcysteine*** 0.01, EtOH 2.78 and 20% NaOH 9.04% as the additives. After a 13-wk incubation at 40.degree., 90% vitamin C and 96% vitamin A remained in the ***compn***.

L5 ANSWER 4 OF 12 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2001:239790 BIOSIS
DOCUMENT NUMBER: PREV200100239790
TITLE: Methods for inhibiting photoaging of skin.
AUTHOR(S): Fisher, Gary J. (1); Voorhees, John J.; Kang, Sewon
CORPORATE SOURCE: (1) Ann Arbor, MI USA
ASSIGNEE: Regents of the University of Michigan
PATENT INFORMATION: US 6130254 October 10, 2000
SOURCE: Official Gazette of the United States Patent and Trademark
Office Patents, (Oct. 10, 2000) Vol. 1239, No. 2, pp. No
Pagination. e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English

AB Methods are provided for ameliorating various effects of UVA and UVB radiation from the sun, comprising administering ***compositions*** including an ingredient that prevents photoaging from MED and subMED radiation, such as a ***retinoid***, certain other compounds (such as ***N*** - ***acetylcysteine***, 2-furildioxime, and vitamin C) and optionally other MMP inhibitors such as tetracyclines and/or compounds that inhibit the P-450-mediated metabolism of ***retinoids*** such as ketoconazole and other azole compounds. In the method, the ***composition*** is applied prior to exposure to the sun; depending upon the ingredients used in the ***composition***, application should be from 7 to 48 hours prior to exposure. Compounds that prevent erythema (skin reddening, sunburn) do not necessarily protect against UV-mediated elevation of MMP levels and activity, and similarly compounds that prevent

UV-mediated elevation of MMP levels and activity are not necessarily effective against UV-induced erythema.

L5 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:722886 CAPLUS
DOCUMENT NUMBER: 131:327568
TITLE: Use of antioxidants for the treatment of inflammatory skin diseases
INVENTOR(S): Glombitza, Stefan
PATENT ASSIGNEE(S): Hexal A.-G., Germany
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9956735	A2	19991111	WO 1999-EP3040	19990504
WO 9956735	A3	19991229		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19819616	A1	19991111	DE 1998-19819616	19980504
AU 9938271	A1	19991123	AU 1999-38271	19990504

PRIORITY APPLN. INFO.: DE 1998-19819616 19980504
WO 1999-EP3040 19990504

AB ***Compns*** . contg. ***N*** - ***acetylcysteine*** or a deriv. thereof, alone or in combination with other antioxidants such as ***ascorbic*** ***acid*** , .beta.-carotene, and .alpha.-***tocopherol*** , are provided which can be administered orally for the treatment or prophylaxis of inflammatory skin diseases such as neurodermatitis, psoriasis, and contact dermatitis. These ***compns*** . avoid the side effects assocd. with topical administration of therapeutic agents for treating these conditions. Preferred daily dosages in adults are: ***N*** - ***acetylcysteine*** , 500-1500 mg; ***ascorbic*** ***acid*** , 0.5-2.5 g; .beta.-carotene, 10-100 mg; .alpha.- ***tocopherol*** , 200-1600 IU.

L5 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:191332 CAPLUS
DOCUMENT NUMBER: 130:209087
TITLE: Prevention of melanin formation in seafood
INVENTOR(S): Alonso, Eduardo G.; Rogert, Normando; Florio, Salvador P.; Panzarasa, Hector E.
PATENT ASSIGNEE(S): Adital, S.A., Argent.
SOURCE: U.S., 3 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5882688	A	19990316	US 1997-858157	19970411

AB A ***compn*** . to prevent melanization in seafood contains potassium or sodium bisulfite, edible org. acids such as citric, tartaric, or ***ascorbic*** ***acid*** (or their salts) and L-cysteine or ***N*** - ***acetylcysteine*** as an enzymic inhibitor, antioxidant, and sequestering agent. Thus, a formulation of sodium bisulfite 110, citric acid 50, ***ascorbic*** ***acid*** 20, L-cysteine 6, and sodium chloride 814 g in 20 L of water is used to prevent melanin formation in shrimps or crayfish.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

L5 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:804144 CAPLUS

DOCUMENT NUMBER: 130:56997

TITLE: Compositions and methods for inhibiting photoaging of skin

INVENTOR(S): Fisher, Gary J.; Voorhees, John J.; Kang, Sewon

PATENT ASSIGNEE(S): Regents of the University of Michigan, USA

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855075	A2	19981210	WO 1998-US11453	19980603
WO 9855075	A3	19990617		
W:		AL, AU, BB, BG, BR, CA, CN, CU, GE, ID, IL, IS, JP, KP, KR, LC, LK, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, TT, UA, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
AU 9880573	A1	19981221	AU 1998-80573	19980603
ZA 9804791	A	19990106	ZA 1998-4791	19980603
EP 998251	A2	20000510	EP 1998-928879	19980603
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI		
US 6130254	A	20001010	US 1998-89914	19980603
BR 9809969	A	20001017	BR 1998-9969	19980603
JP 2001520677	T2	20011030	JP 1999-502833	19980603
NO 9905768	A	20000117	NO 1999-5768	19991125
US 6365630	B1	20020402	US 2000-615218	20000713
PRIORITY APPLN. INFO.:			US 1997-48520P	P 19970604
			US 1997-57976P	P 19970905
			US 1998-89914	A3 19980603
			WO 1998-US11453	W 19980603

AB ***Compns*** . and methods are provided for ameliorating various effects of UVA and UVB radiation from the sun. The ***compns*** including an ingredient that prevents photoaging from MED (min. erythema dose) and subMED radiation, such as a ***retinoid***, certain other compds. (such as ***N*** - ***acetylcysteine***, 2-furildioxime, and vitamin C) and optionally other MMP (matrix metalloproteinases) inhibitors such as tetracyclines and/or compds. that inhibit the P 450-mediated metab. of ***retinoids*** such as ketoconazole and other azole compds. In the method, the ***compn*** is applied prior to exposure to the sun; depending upon the ingredients used in the ***compn***, application should be from 7 to 48 h prior to exposure. Compds. that prevent erythema (skin reddening, sunburn) do not necessarily protect against UV-mediated elevation of MMP levels and activity, and similarly compds. that prevent UV-mediated elevation of MMP levels and activity are not necessarily effective against UV-induced erythema. Examples are given showing melatonin and vitamin E provide good anti-sunburn sunscreen effect.

L5 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:366646 CAPLUS

DOCUMENT NUMBER: 127:23766

TITLE: Medical food composition for metabolic detoxification

INVENTOR(S): Bland, Jeffrey S.

PATENT ASSIGNEE(S): Bland, Jeffrey S., USA

SOURCE: U.S., 7 pp. Cont. of U. S. Ser. No. 815,290, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5629023	A	19970513	US 1993-156090	19931122
US 5637324	A	19970610	US 1995-463628	19950606
PRIORITY APPLN. INFO.:			US 1991-815290	19911231
			US 1993-156090	19931122

AB A medical food which is administered for several days as the sole source or as a substantial source of the daily caloric intake of a patient suffering from metabolic poisoning is disclosed. The ***compn*** contains 45 to 65% protein conc.; 2.5 to 17.5% of grain syrup solids contg. 50% dextran; 2.5 to 17.5% of grain syrup solids contg. 50% of maltose; 3 to 12% of oil contg. 20% of oleic acid, 1 to 11% medium chain triglycerides; magnesium ions; buffering agent; sol. calcium salt; ***ascorbic*** ***acid*** ; 0.40 to 0.65% of .beta.-carotene; D-.alpha.- ***tocopherol*** ; chromium ions in the trivalent or hexavalent form, 0.008 to 0.022% glutathione, 0.08 to 0.22% ***N*** - ***acetylcysteine*** ; L-lysine hydrochloride; 0.08 to 0.22% L-threonine, and 0.08 to 0.22% of L-cysteine. Patients were orally administered the above ***compn*** . for 25 days. All patients showed a shorter caffeine "half life" (indicating improved cytochrome P 450 activity), and a larger output of hippuric acid (indicating improve ability of the liver to detoxify benzoic acid by conjugation with glycine).

L5 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1996:130878 CAPLUS
 DOCUMENT NUMBER: 124:185565
 TITLE: Method for the treatment, prevention or minimization of hair loss
 INVENTOR(S): Sharpe, Richard J.; McCaloon, Maureen H.; Arndt, Kenneth A.; Galli, Stephen J.
 PATENT ASSIGNEE(S): Arcturus Pharmaceutical Corp., USA
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9534303	A1	19951221	WO 1995-US7470	19950613
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9528252	A1	19960105	AU 1995-28252	19950613
PRIORITY APPLN. INFO.:			US 1994-258758	19940613
			WO 1995-US7470	19950613

AB A compn. and method for the treatment, prevention or minimization of hair loss that provides for the topical administration of an effective amt. of lipid sol. thioester or thioether of N-acetylcysteine.

L5 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1994:279861 CAPLUS
 DOCUMENT NUMBER: 120:279861
 TITLE: Use of radical catchers as immunomodulating agents in cosmetic and dermatological compositions
 INVENTOR(S): Degwert, Joachim; Gers-Barlag, Heinrich; Van Den Broeke, Loen T.; Beijersbergen Van Henegouwen, Gerhard M. J.
 PATENT ASSIGNEE(S): Beiersdorf A.-G., Germany; Rijksuniversiteit Leiden
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO. 9404128 A2 19940303 WO 1993-DE773 19930824
 WO 9404128 A3 19940
 W: AU, JP, US
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 DE 4228455 A1 19940915 DE 1992-4228455 19920826
 DE 4305788 A1 19940901 DE 1993-4305788 19930225
 DE 4305788 C2 19970612
 EP 656773 A1 19950614 EP 1993-918914 19930824
 EP 656773 B1 19970402
 R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE
 JP 08506085 T2 19960702 JP 1993-505780 19930824
 AT 150960 E 19970415 AT 1993-918914 19930824
 ES 2102670 T3 19970801 ES 1993-918914 19930824
 AU 690075 B2 19980423 AU 1993-49422 19930824
 WO 9418942 A1 19940901 WO 1994-DE78 19940129

W: CN, JP, US
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 EP 686026 A1 19951213 EP 1994-904978 19940129
 EP 686026 B1 19970903
 R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL
 JP 08506818 T2 19960723 JP 1994-518529 19940129
 AT 157536 E 19970915 AT 1994-904978 19940129
 ES 2108422 T3 19971216 ES 1994-904978 19940129
 US 5780042 A 19980714 US 1996-495497 19960208

PRIORITY APPLN. INFO.:

DE 1992-4228455 A 19920826
 DE 1993-4305788 A 19930225
 WO 1993-DE773 W 19930824
 WO 1994-DE78 W 19940129

OTHER SOURCE(S): MARPAT 120:279861

AB Cosmetic or dermatol. ***compsns*** for treating and/or preventing UV-B radiation-induced immunosuppression are characterized by a therapeutically or cosmetically effective content of .gtoreq.1 radical scavengers chosen from thiols and derivs., ***tocopherols*** and derivs., and 2,4-O-furfurylidenesorbitol and its alkyl ethers. Thus, a lotion was prepd. contg. ***N*** - ***acetylcysteine*** (active ingredient) 0.300, cyclomethicone 2.000, cetyltrimethicone copolyol 0.200, PEG-22 didecyl copolymer 3.000, paraffin oil 2.000, caprylic-capric triglyceride 5.800, octyl methoxycinnamate 5.800, butyl(methoxy)dibenzoylmethane 4.000, ZnSO4 0.700, Na4EDTA 0.300, perfume, preservative, dye, and water to 100.000 wt.%. When stimulator lymphocytes were irradiated with UV in the presence of ***N*** - ***acetylcysteine*** prior to incubation with responder lymphocytes, the suppression of the mixed lymphocyte reaction by UV was prevented.

L5 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1992:657989 CAPLUS
 DOCUMENT NUMBER: 117:257989
 TITLE: Acetylcysteine-containing skin-regenerating cosmetics
 INVENTOR(S): Barbarics, Eva; Muller, Maria; Imre, Janos; Kern, Jozsef
 PATENT ASSIGNEE(S): Hung.
 SOURCE: Hung. Teljes, 9 pp.
 CODEN: HUXXB
 DOCUMENT TYPE: Patent
 LANGUAGE: Hungarian
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 60124	A2	19920828	HU 1990-6238	19900927
HU 209867	B	19941128		

AB A skin-regenerating cosmetic compn. comprises N-acetyl-L-cysteine (I) and, optionally, panthenol and vitamins. A night cream contained I 1.0, lanalcol 1.7, white wax 3.3, cetylstearyl alc. 6.6., castor oil 21.5, stearin 5.0, sunflower oil 10.0, ascorbic acid 1.0, retinol 0.3, tocopherol 0.3, panthenol 1.5, chamomile ext. 10.0, benzoin ext. 2.0, and water to 100.0 g.

L5 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:520635 CAPLUS
 DOCUMENT NUMBER: 111:120635

TITLE: . Antioxidant skin cosmetics containing ascorbyl esters
and thiols and complexing agents
INVENTOR(S): Nguyen, Quang Lan; Griat, Jacqueline; Millecamps,
Francois
PATENT ASSIGNEE(S): Oreal S. A., Fr.
SOURCE: Fr. Demande, 16 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2610626	A1	19880812	FR 1987-1539	19870209
FR 2610626	B1	19890519		
EP 280606	A1	19880831	EP 1988-400283	19880208
EP 280606	B1	19920415		

R: BE, CH, DE, FR, GB, IT, LI, NL

JP 63225689	A2	19880920	JP 1988-25874	19880208
US 5023235	A	19910611	US 1988-153450	19880208

PRIORITY APPLN. INFO.: FR 1987-1539 19870209

AB Cosmetics contain an antioxidant ***compn*** based on .gtoreq.1 stabilized ascorbate esters, .gtoreq.1 complexing agents, and .gtoreq.1 thiols. The cosmetics protect the lipids in the skin from oxidn. Suitable complexing agents are EDTA, penta-Na diethylenetriaminepentaacetate, hexadecylamine salicylate, citric acid, tartaric acid, Na tartrate, phytic acid, dibenzylidithiocarbamate, or their mixts. Suitable thiols are ***N*** - ***acetylcysteine***, glutathione, or their mixts. A preferred antioxidant system contains ***tocopherols*** or caffeic acid 2.5-20, ascorbate ester 20-70, complexing agent 20, and thiol 30% by wt. The degree of degrdn. of ascorbyl palmitate (I) after storage for 40 days in form of a mixt. contg. I 0.05, ***N*** - ***acetylcysteine*** 0.01, and EDTA 0.01% by wt. was 30%, whereas I had completely decompd. in a mixt. contg. I and EDTA or I and ***N*** - ***acetylcysteine***. A mixt. contg. I 0.20, hexadecylamine salicylate 0.20, ***N*** - ***acetylcysteine*** 0.10, and ***tocopherols*** 0.20% by wt. stabilized vitamin F against oxidn. for 114 min, whereas oxidn. was induced within 15 min in the absence of stabilizers or in the presence of 0.20% by wt. hexadecylamine salicylate alone and 0.1% by wt. ***N*** - ***acetylcysteine*** alone, and within 60 min in the presence of ***tocopherols*** as stabilizers. An antioxidant system contained I 76, citric acid 16, and ***N*** - ***acetylcysteine*** 8% by wt. A skin cream in the form of a water-in-oil emulsion contained Mg lanolate 14.4, lanolin alc. 3.6, tournesol oil 40.0, iso-Pr myristate 8.0, ozokerite 4.0, vitamin F 2.0, ***ascorbic*** ***acid*** 0.5, soy lecithin 5, ***tocopherols*** 0.25, I 1.0, glutathione 0.1, ***N*** - ***acetylcysteine*** 0.05, citric acid 0.05, EDTA 0.15, perfume 0.8, methylparaben 0.3, and H2O to 100% by wt.

=> d his

(FILE 'HOME' ENTERED AT 19:13:14 ON 24 APR 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 19:13:53 ON 24 APR 2002

L1 311380 S RETINOID OR CHOLECIFEROL OR (VITAMIN K) OR TOCOPHEROL OR (ASC
L2 24378 S N-ACETYLCYSTEINE OR ACETYLCYSTEINE
L3 767 S L1 (P) L2
L4 12 S L3 (P) COMPOSITION
L5 12 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)

=> s retinoid (p) tocopherol (p) (ascorbic acid)
L6 67 RETINOID (P) TOCOPHEROL (P) (ASCORBIC ACID)

=> s 16 (p) 12
L7 5 L6 (P) L2

=> duplicate remove 17
DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L7
L8 1 DUPLICATE REMOVE L7 (4 DUPLICATES REMOVED)

=> s l8 not l5
L9 1 L8 NOT L5

=> d l9 1 ibib abs

L9 ANSWER 1 OF 1 MEDLINE
ACCESSION NUMBER: 95111119 MEDLINE
DOCUMENT NUMBER: 95111119 PubMed ID: 7811993
TITLE: Regulation of apoptosis induced by the retinoid
N-(4-hydroxyphenyl) retinamide and effect of deregulated
bcl-2.
AUTHOR: Delia D; Aiello A; Formelli F; Fontanella E; Costa A;
Miyashita T; Reed J C; Pierotti M A
CORPORATE SOURCE: Istituto Nazionale Tumori, European Institute of Oncology,
Milan, Italy.
CONTRACT NUMBER: CA-47956 (NCI)
CA-60181 (NCI)
SOURCE: BLOOD, (1995 Jan 15) 85 (2) 359-67.
Journal code: A8G; 7603509. ISSN: 0006-4971.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199502
ENTRY DATE: Entered STN: 19950217
Last Updated on STN: 19950217
Entered Medline: 19950203

AB The cancer chemopreventive ***retinoid*** N-(4-hydroxyphenyl)-all-
trans retinamide (HPR) was recently shown by us to have antiproliferative
and apoptotic effects on human leukemic cell lines, including those
unresponsive to all-trans retinoic acid (ATRA). We have now characterized
further the process of HPR-induced cell death. We report that inhibitors
of RNA transcription and of protein synthesis, activators of protein
kinase C (PKC), inhibitors of tyrosine kinases, Zn++, and the antioxidants
acetylcysteine, ***ascorbic***, ***acid***, alpha-
tocopherol, and deferoxamine suppressed HPR-induced apoptosis.
HL60 cells induced toward monocytic differentiation by 1,25
dihydroxyvitamin-D3 [1,25(OH)2D3], but not those induced toward the
granulocytic differentiation by ATRA, showed reduced responses to HPR. The
transport of HPR by cells with different sensitivity to the
retinoid, however, was similar, even after treatment with the
phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), which induces
unresponsiveness to HPR. The expression of the apoptosis-related genes
bcl-2, p53, and c-myc was examined to determine their role in
HPR-triggered cell death. The levels of bcl-2 mRNA were markedly
diminished by 24 hours of HPR treatment in all cell lines except in the
relatively HPR-insensitive line K422. However, probably because of its
long half-life, bcl-2 protein levels were either unchanged or only
slightly decreased. Downregulation of p53 mRNA was also observed within 24
hours of HPR exposure in NB4 but not K422 cells, but no changes in the
amount of p53 protein were found. Suppression of c-myc transcription was
observed in all cells except K422. The protective role of bcl-2 on cell
death by HPR was investigated in HL60 as well as 697 pre-B leukemia and
Jurkat T-acute lymphocytic leukemia (T-ALL) cells constitutively
expressing high levels of bcl-2 proteins due to gene transfer
manipulation. Compared with control cells, the onset of apoptosis in these
cells with deregulated bcl-2 production was delayed by at least 24 hours.
These findings establish that cell death by HPR requires RNA transcription
and protein synthesis and is regulated by the activation of PKC. Although
changes in bcl-2, p53, and c-myc expression are found in cells treated
with HPR, the time-course of these events suggests that HPR-triggered
apoptosis is not directly controlled by these genes. Finally, while
ectopic overexpression of bcl-2 does not protect cells from death by HPR,
it markedly delays its onset. (ABSTRACT TRUNCATED AT 400 WORDS)

=> s retinoid (p) (ascorbic acid)
L10 177 RETINOID (P) (ASCORBIC ACID)

=> d his

(FILE 'HOME' ENTERED AT 19:13:14 ON 24 APR 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 19:13:53 ON 24 APR 2002

L1 311380 S RETINOID OR CHOLECIFEROL OR (VITAMIN K) OR TOCOPHEROL OR (ASC
L2 24378 S N-ACETYLCYSTEINE OR ACETYLCYSTEINE
L3 767 S L1 (P) L2
L4 12 S L3 (P) COMPOSITION
L5 12 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)
L6 67 S RETINOID (P) TOCOPHEROL (P) (ASCORBIC ACID)
L7 5 S L6 (P) L2
L8 1 DUPLICATE REMOVE L7 (4 DUPLICATES REMOVED)
L9 1 S L8 NOT L5
L10 177 S RETINOID (P) (ASCORBIC ACID)

=> s l10 (p) l2

L11 5 L10 (P) L2

=> duplicate remove l11

DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L11

L12 1 DUPLICATE REMOVE L11 (4 DUPLICATES REMOVED)

=> s l12 not (l9 or l4)

L13 0 L12 NOT (L9 OR L4)

=> d his

(FILE 'HOME' ENTERED AT 19:13:14 ON 24 APR 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 19:13:53 ON 24 APR 2002

L1 311380 S RETINOID OR CHOLECIFEROL OR (VITAMIN K) OR TOCOPHEROL OR (ASC
L2 24378 S N-ACETYLCYSTEINE OR ACETYLCYSTEINE
L3 767 S L1 (P) L2
L4 12 S L3 (P) COMPOSITION
L5 12 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)
L6 67 S RETINOID (P) TOCOPHEROL (P) (ASCORBIC ACID)
L7 5 S L6 (P) L2
L8 1 DUPLICATE REMOVE L7 (4 DUPLICATES REMOVED)
L9 1 S L8 NOT L5
L10 177 S RETINOID (P) (ASCORBIC ACID)
L11 5 S L10 (P) L2
L12 1 DUPLICATE REMOVE L11 (4 DUPLICATES REMOVED)
L13 0 S L12 NOT (L9 OR L4)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

65.73

65.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-6.82

-6.82

STN INTERNATIONAL LOGOFF AT 19:21:19 ON 24 APR 2002